Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Direxion Daily S&P 500 Bear 3X Shares ETF
SPXS
5
ProShares UltraPro Short S&P500 ETF
SPXU
US Stock MarketDetailed Quotes
THAR Tharimmune
- 1.530
- -0.020-1.28%
Close May 2 16:00 ET
- 1.570
- +0.040+2.61%
Post 20:01 ET
3.23MMarket Cap-0.16P/E (TTM)
1.575High1.413Low143.73KVolume1.530Open1.550Pre Close213.80KTurnover6.92%Turnover RatioLossP/E (Static)2.11MShares6.44952wk High2.47P/B3.18MFloat Cap0.95252wk Low--Dividend TTM2.08MShs Float1590.000Historical High--Div YieldTTM10.48%Amplitude0.952Historical Low1.487Avg Price1Lot Size
Market Insights
Discussing
BRK cash at new high: What to expect from Buffett’s meeting?
🎙️Discussion 1. Buffett said he won't sell Japanese stocks for the next ten years. What's your take? 2. In the face of market changes, do y
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Tharimmune Stock Forum
Breakthrough Drug TH104 Clinical Data Selected for Two Premier Medical Conferences DDW and EASL
$Glucotrack (GCTK.US)$ 21.66%
$Greenlane (GNLN.US)$ 32.77%
$Jaguar Health (JAGX.US)$ 27.15%
$Nvni Group (NVNI.US)$ 161.08% RUNNER
$Eightco Holdings (OCTO.US)$ 25.90%
$Petros Pharmaceuticals (PTPI.US)$ 59.51%
$Stem Inc (STEM.US)$ 27.39%
$Siyata Mobile (SYTA.US)$ 15%
$Tharimmune (THAR.US)$ 27.07%
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If ...
Benzinga· 4 mins ago
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Monday, 28th April at 8:01 am
BRIDGEWATER, NEW JERSEY / ACCESS Newswire / April 28, 2025 / Tharimmune, Inc., (NASDAQ: THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, recently announced positive feedback from the U.S. Food and Drug A...
Tharimmune's preclinical data announcement marks a meaningful advancement for their multispecific antibody platform. The company's EpiClick technology appears to be delivering on its promise of accessing novel epitopes with two key candidates now showing promising in vitro potency.
The PD-1/VEGF bispecific (HS1940) represents a rational combination of immuno-oncology and anti-angiogenesis approaches. With EC50 values of 2.1nM for PD-1 and 2.56nM for VEG...
This preclinical data release demonstrates Tharimmune's progress in leveraging their EpiClick platform to produce differentiated oncology assets. Both candidates target well-validated oncology pathways but with potentially novel approaches to epitope binding.
The PD-1/VEGF bispecific space has become increasingly competitive, with Summit Therapeutics' ivonescimab leading development in the US market. Tharimmune's HS1940 attempts differentiation ...
Breakthrough Cancer Drug Shows Superior Design: Tharimmune's Dual-Target Biologic Outperforms Competition
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
Monday, 7th April at 8:00 am
BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced preclinical data from its expanded pipeline with HS1940, a dual-target multispe...
FDA Fast-Tracks Tharimmune's Revolutionary Opioid Defense Drug: No Clinical Trials Needed
No comment yet